New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

ATLANTA -- Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week in Atlanta. Read More

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
Eaton Introduces Higher Power Fuses for Electrified Commercial Vehicles
Red Lobster Chain Goes Bankrupt After Unlimited Shrimp Deal